Skip to main content
Premium Trial:

Request an Annual Quote

Recent Key Deals Between RNAi Drug Developers and Big Pharma/Biotech

Premium
Eli Lilly management last week highlighted the most promising drug candidates in the company’s pipeline, including two antisense-based drugs currently in the clinic for cancer (see related story, this issue). Despite Lilly’s early look at the RNAi field though its now-expired 2004 collaboration with Sirna Therapeutics, the drugs giant has yet to embrace RNAi as a therapeutic modality.
 
Other big players in the pharmaceutical, biotech, and medical device fields, however, have taken steps to incorporate RNAi into their drug-development efforts. Below is a snapshot of key alliances between big pharma/biotech and RNAi firms.
 

File Attachments
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.